Vanguard Group Inc. decreased its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 16.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,838,169 shares of the biopharmaceutical company's stock after selling 922,280 shares during the quarter. Vanguard Group Inc. owned about 7.91% of Sage Therapeutics worth $26,271,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently added to or reduced their stakes in the business. State Street Corp raised its stake in shares of Sage Therapeutics by 18.2% during the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company's stock valued at $21,127,000 after purchasing an additional 451,377 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Sage Therapeutics by 157.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 169,057 shares of the biopharmaceutical company's stock valued at $918,000 after purchasing an additional 103,495 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in Sage Therapeutics by 108.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 74,625 shares of the biopharmaceutical company's stock worth $405,000 after buying an additional 38,876 shares during the period. Fox Run Management L.L.C. lifted its holdings in Sage Therapeutics by 199.0% in the 4th quarter. Fox Run Management L.L.C. now owns 48,950 shares of the biopharmaceutical company's stock worth $266,000 after buying an additional 32,579 shares in the last quarter. Finally, Amundi purchased a new position in Sage Therapeutics in the 4th quarter valued at about $166,000. 99.22% of the stock is owned by hedge funds and other institutional investors.
Sage Therapeutics Stock Up 3.4 %
Shares of SAGE stock opened at $7.40 on Tuesday. The firm has a fifty day moving average of $7.45 and a 200-day moving average of $6.71. The company has a market capitalization of $454.96 million, a price-to-earnings ratio of -1.12 and a beta of 0.48. Sage Therapeutics, Inc. has a 12-month low of $4.62 and a 12-month high of $15.74.
Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. On average, equities analysts expect that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a research report on Wednesday, February 12th. HC Wainwright reaffirmed a "neutral" rating and issued a $12.00 price target (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Wedbush reissued a "neutral" rating and set a $6.00 price objective on shares of Sage Therapeutics in a report on Wednesday, February 12th. Scotiabank dropped their target price on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating for the company in a research report on Wednesday, February 12th. Finally, Canaccord Genuity Group reduced their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research report on Wednesday, February 12th. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Sage Therapeutics has a consensus rating of "Hold" and an average target price of $8.81.
View Our Latest Analysis on SAGE
Sage Therapeutics Profile
(
Free Report)
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sage Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.
While Sage Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
